Gamida Cell Ltd (NASDAQ:GMDA) was the target of a significant decrease in short interest in November. As of November 15th, there was short interest totalling 44,800 shares, a decrease of 5.1% from the October 31st total of 47,200 shares. Currently, 0.4% of the company’s stock are sold short. Based on an average daily trading volume, of 30,300 shares, the days-to-cover ratio is presently 1.5 days.
A number of large investors have recently made changes to their positions in the business. Millennium Management LLC grew its stake in Gamida Cell by 4.6% in the 3rd quarter. Millennium Management LLC now owns 69,077 shares of the company’s stock valued at $299,000 after purchasing an additional 3,017 shares during the period. Royal Bank of Canada bought a new position in Gamida Cell in the 2nd quarter valued at $71,000. Phoenix Holdings Ltd. bought a new position in Gamida Cell in the 3rd quarter valued at $121,000. Bank Hapoalim BM bought a new position in Gamida Cell in the 2nd quarter valued at $195,000. Finally, EcoR1 Capital LLC bought a new position in Gamida Cell in the 2nd quarter valued at $265,000. Hedge funds and other institutional investors own 23.99% of the company’s stock.
Shares of Gamida Cell stock opened at $5.12 on Monday. The stock has a fifty day simple moving average of $4.85 and a 200 day simple moving average of $5.00. Gamida Cell has a 12-month low of $2.93 and a 12-month high of $15.41. The company has a market capitalization of $121.11 million and a P/E ratio of -0.49. The company has a current ratio of 7.61, a quick ratio of 7.60 and a debt-to-equity ratio of 0.09.
Several equities research analysts recently issued reports on GMDA shares. JMP Securities started coverage on Gamida Cell in a report on Friday, September 20th. They set an “outperform” rating and a $16.00 price target for the company. Oppenheimer set a $18.00 price target on Gamida Cell and gave the stock a “buy” rating in a report on Wednesday, August 7th. Finally, Zacks Investment Research downgraded Gamida Cell from a “buy” rating to a “hold” rating in a report on Wednesday, October 9th.
About Gamida Cell
Gamida Cell Ltd. is a clinical stage biopharmaceutical company, which engages in the development of cell therapies that are designed to cure cancer and rare serious hematologic diseases. Its products pipeline include NiCord and NAM-NK. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.
Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.